/
Neurology
Duchenne Muscular Dystrophy (DMD)
8
Pipeline Programs↗
10
Active Trials↗
5
Companies Involved↗
Duchenne Muscular Dystrophy (DMD) is an early-stage landscape with 8 programs across 5 companies. The most active players are Entrada Therapeutics, Inc., BioMarin Pharmaceutical, Dyne Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 23
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
12
clinical trials
Recruiting5 · 42%
Not yet recruiting3 · 25%
Completed2 · 17%
Active, not recruiting1 · 8%
Enrolling by invitation1 · 8%
Clinical Trials
Trial Activity
12 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)